TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants With Treatment-Related Adverse Events
Endpoint domain: Adverse events/effects
Endpoint subdomain: null
Primary endpoint: Active ROM of shoulder joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessed using visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variants associated with healthy pre-mature CAD phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Metabolomic fingerprints associated with healthy pre-mature CAD phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post Operative Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL-ox levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pathological Tumor Regression Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Urinary Symptom Questionnaire for Neurogenic Bladder-Intermittent Catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Patient Satisfaction Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality and intensity of pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Covid-19 recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects acquiring a Motor Milestone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects without residual fragments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Oxyhaemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total Haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of NCDs reduced among the adults (>/= 18 years)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of adherence to medication and lifestyle modification measures change among the people with NCDs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The proportion of people with control of hypertension, lung function, and blood sugar increased
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day point prevalence abstinence from combustible tobacco use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of obesity-related activities in primary health care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total PVWMH extent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total CC-PVWMH extent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Capivasertib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of Capivasertib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of Capivasertib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful identification of the phrenic nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depth of phrenic nerves measured by ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance between phrenic nerve and cervical structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in N100 Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in N100 Latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in blood biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Behavior Rating Inventory of Executive Function (BRIEF)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Electrodncephalogram (EEG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Expression of viral entry factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of ZX-101A
Endpoint domain: Adverse events/effects
Primary endpoint: Mini-BesTEST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trunk Impact Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ABO gene polymorphism (rs8176746) in gastric and colorectal cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Nutrition status of persons with dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nutrition status of caregivers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Owestry Disability Index (ODI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in short International Falls efficacy scale (sFES-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time-weighted average change in symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days with symptoms
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Rate of patients with 68Ga-PSMA-PET positive lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Persistence of the biosimilar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation of the biosimilar
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Hospital readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Satisfaction assessed by SUCMA 14 Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Magnitude of Troponin fragmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Average time for health monitoring operation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hoehn-Yahr Classification of Disability Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jebsen Taylor Hand Function test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parkinson's Disease Questionnaire (PDQ-8)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Active Joint Position Sense (AJPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of composite cardiac events
Endpoint domain: Mortality/survival
Primary endpoint: Change of 1-year lipid core burden index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Alive and free of respiratory failure at Day 29
Endpoint domain: Mortality/survival
Primary endpoint: Breathing sounds average power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SaO2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage Body Fat (PBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Glenoid version deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glenoid inclination deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: VAS scores during cervical dilation and uterine aspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of good-quality embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ejection fraction Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Implantation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of subjects with new myelofibrosis, new cataract, or existing cataract progression
Endpoint domain: Adverse events/effects
Primary endpoint: Cortical activation responses to nociceptive stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neuro-vegetative responses to nociceptive stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower gastrointestinal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in the scores of the Frequency of Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in time of the Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Scale in Self-Efficacy Eating Consumption Scale (SEECS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the Self-Efficacy for Exercise Questionnaire (SEEQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the Sedentary behavior questionnaire (SBQ-s)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diagnostic quality risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thoracic aorta values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of pregabalin in chronic lower back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in the thickness of supraspinatus tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Evolution of anti-human leucocyte antigen sensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in CTCAE grading scale of chronic low grade non hematologic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of CBD in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of CBD-OH in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of THC in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of THC-COOH in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of 11-OH-THC in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Auditory Brainstem Response (ABR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Otoacoustic Emissions (OAE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: extent of aGVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Mean DFUWI score (total AUC) for TP-102 versus Placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients that achieve a 50% reduction in wound surface area by week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of patients having had an osteoarticular infection due to S. aureus
Endpoint domain: Adverse events/effects
Primary endpoint: Blood serum concentrations of GFAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood plasma concentrations of GFAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperative systolic velocity peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intraoperative QFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in treatment related death
Endpoint domain: Mortality/survival
Primary endpoint: rate of completion of protocol treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of positive microbial wound cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in serum concentration of dalbavancin in plasma (mcg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of intraprocedural pain
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of intraprocedural nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration of siRNA-TGF-B1 and siRNA-COX-2 in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ischemic stroke, hemorrhagic stroke, or transient ischemic attack
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in best-corrected distance visual acuity (BCDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Major Adverse Cardiac and Cerebrovascular Events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in total volume of new cerebral lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relative difference in weight loss at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline to Week 13 in UACR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Perceived parental role
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parental adjustment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: composite outcome 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: frequency and severity of DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: rate of patient withdrawal due to AE/Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of DMI for intrahepatic tumor detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Skeletal muscle severity outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cardiac muscle severity outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Premature progesterone elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Oxidative stress level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High-risk driving events
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Severity of Acute Radiation Dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: measurement performance (bias and %bias)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: measurement performance (regression)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: measurement performance (CV and SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of 18F FLT signal uptake abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of 18F FLT uptake in marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean differences of 18F FLT uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Post-intervention change in self-rated hunger
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: N2 ERP amplitude (in microvolts)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Task accuracy from the behavioral response during the Alcohol Cued Go/No-Go task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction time from the behavioral response during the Alcohol Cued Go/No-Go task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in The 10 Metre Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum expression of pentraxin 3 (PTX3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum expression of uromodulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: association with endothelial dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: association with mitochondrial injury in sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of LV thrombus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effect on gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of energy intake between rest and exercise conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of total energy expenditure post-experimentation between rest and exercise conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Treatment-Emergent Serious Adverse Events (TESAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Life-threatening infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hematologic malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Solid tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Weeks of Lactation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Parents who Exclusively Breastfed their Infant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of deterioration and complications
Endpoint domain: Adverse events/effects
Primary endpoint: CSF biomarkers of target engagement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CSF biomarkers of AD pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CSF biomarkers of neurodegeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of participants with plasma HIV-1 RNA level > 50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Concordance of sleep hypopnea and apnea counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Normalization of Serum Potassium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 30-day postoperative outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of SBRT
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Yale Food Addiction Scale 2.0 (YFAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physical Fitness Assessment (weight)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of HBV reactivation
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC(0-inf)) of Lu AG06466
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Lu AG06466
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Elimination Half-life (t1/2) of Lu AG06466
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain during examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement rate of main clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: walking speed for obstacle task negotiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: score on test of executive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Risk of hypertensive disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Erythrocyte (RBC) folic acid concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Adverse events after CEA CAR-T cells infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Obtain the maximum tolerated dose of CEA CAR-T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Triage Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Program Attendance Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Measurement Completion Rate (Baseline)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Measurement Completion Rate (12 Weeks)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Measurement Completion Rate (6 Months)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use